Comparison of ixekizumab with ustekinumab in moderate‐to‐severe psoriasis: 24‐week results from IXORA‐S, a phase III study

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

Related Topics

    loading  Loading Related Articles